There is, however, no pharmacological treatment currently approved to treat hydrocephalus. Additionally, nearly 20 percent of patients with normal pressure hydrocephalus also have type 2 diabetes and take sodium/glucose cotransporter 2 (SGLT2) inhibitors to manage their blood sugar.
"The drug also lowered patients' blood sugar levels by 1.3% on average, while the overall efficacy of orforglipron in promoting weight loss and controlling diabetes has been met with enthusiasm."